Evidence supporting the use of: Marine lipid
For the health condition: Angina

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Marine lipids, particularly omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their cardiovascular benefits, including their use in supporting or treating angina pectoris. Scientific validation for their role in angina is moderate. Mechanistically, omega-3 fatty acids are known to reduce triglycerides, lower blood pressure, decrease platelet aggregation, and exert anti-inflammatory effects, all of which can contribute to improved cardiovascular health and reduced ischemic events.

Clinical studies provide mixed evidence regarding the direct impact of marine lipids on angina symptoms. Some randomized controlled trials and meta-analyses suggest that regular intake of omega-3 fatty acids is associated with a reduction in cardiovascular events, which indirectly supports their use in angina management. For example, the GISSI-Prevenzione trial demonstrated reduced cardiovascular death in post-myocardial infarction patients supplementing with omega-3s. However, specific studies focusing solely on angina symptoms (such as frequency or severity of chest pain) are limited, and results are not universally positive.

Guidelines from major cardiology associations (such as the American Heart Association) endorse omega-3 fatty acids for general cardiovascular risk reduction, particularly in secondary prevention. Their use in angina is generally as an adjunct to conventional therapies, rather than as a primary treatment. In summary, there is moderate scientific evidence supporting the cardiovascular benefits of marine lipids, which may extend to angina management, but the evidence is stronger for overall heart health than for direct angina symptom relief.

More about Marine lipid
More about Angina